Potential to return to greatness with the approval of a breakthrough cancer therapy later this year. - Recensione dipendente - Associate Director presso Merck

3,0
25 mar 2014
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Some very bright people still remain, although many excellent people have left. Vacation policy is generous.

Svantaggi

Constant layoffs, and too much focus on financial results, and not enough on the patient. Employee morale is low. Senior management, with the exception of the Research division president, is poor. Raises are sub-inflation on average. Bonuses lower this year than in any year in recent memory.

Esplora altre recensioni su Merck

5,0
9 giu 2026
Dipendente anonimo
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Pension plan is great with high proportion

Svantaggi

Slow promotion and too much meetings

4,0
2 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Over my tenure, I had the opportunity to work alongside highly talented and mission-driven colleagues dedicated to improving patient outcomes. The organization provided exposure to cross-functional collaboration, leadership development opportunities, and meaningful work supporting healthcare providers, patients, and community stakeholders. I appreciated the company's commitment to innovation, professional growth, and serving patients through scientific advancement.

Svantaggi

Like many large organizations, priorities and organizational structures evolved over time, which occasionally created uncertainty and changes in responsibilities. Decision-making processes could sometimes be complex due to the size of the organization, and navigating multiple layers of stakeholders occasionally impacted speed and execution.

Vedi recensioni per: Utile|Valutazione|Data|Tutto